Effects of the Β-Adrenoceptor Blocker Carvedilol in Short QT Syndrome Caused by N588K Mutation in Herg: A Simulation Study

Cunjin Luo,Linghua Li,Tong Liu,Kuanquan Wang,Xiangyun Bai,Ying He,Henggui Zhang

DOI: https://doi.org/10.22489/cinc.2018.166

2018-01-01

Abstract:The short QT syndrome (SQTS) is associated with shortening of QT interval resulting from an accelerated cardiac repolarization. The SQT1, SQTS variant, results from a gain-of-function N588K-KCNH2 mutation in the rapid delayed rectifier potassium current (IKr) channels. Since β - Adrenoceptor blocker can block slow delayed rectifier potassium currents (IKs) and IKr we used in silico approach to evaluate carvedilol's effects on SQT1. Mathematical models of human ventricular action potential (AP) developed by ten Tusscher et al. were modified to incorporate a Markov chain formulation of IKr describing the SQT1 mutant condition. AP models were incorporated into a transmural strand for investigation of QT interval changes. In addition, the simulated IKs and IKr inhibition to prolong the QT interval in SQT1 was quantified. The blocking effects of carvedilol on IKs and IKr were modelled by using Hill coefficient and IC50 from literatures (10 μ M carvedilol reduced IKr in Wild Type- and N588K-KCNH2 by 92.8% and 36.0%; it reduced IKs by 36.5% in both conditions). At single cell level, carvedilol prolonged the AP duration (APD) in SQT1; at strand level, the effects of carvedilol normalized the QT interval in SQT1 from 286 ms to 364 ms. Simulations identified β - Adrenoceptor blocker carvedilol as a potential drug for SQTS treatment.